Carrie Cox
Title: EVP & president, Global Pharmaceuticals, Schering-Plough
The 2006 acquisition of Organon's $3 billion prescription franchise is paying off, helping Cox boost her division's sales by 40% to $14.3 billion in 2008 (it accounts for 77% of total revenue).
Schering-Plough now has five products, including Nasonex and Vytorin, with more than $1 billion in sales -- up from zero in 2003 when Cox came on board. Analysts say Merck will probably find Cox a top spot when it completes its acquisition of Schering.
More galleries
